single page -

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	0.07	-22.37	0.38	-0.99	-10.19	0.31	-0.46	-21.09
2023-10-01	2023-12-31	0.21	-16.34	-8.80	-0.73	-0.07	-9.01	-0.14	-22.10
2023-10-01	2023-12-31	0.21	-16.34	-8.80	-0.73	-0.07	-9.01	-0.14	-22.10
2023-07-01	2023-09-30	0.00	-5.05	-2.58	-0.23	-1.68	-2.58	-0.09	-12.87
2023-07-01	2023-09-30	-	-5.04	-2.58	-0.23	-5.49	-2.58	-0.09	-12.87
2023-04-01	2023-06-30	0.00	-13.00	3.72	-0.58	-0.28	3.72	-0.08	-12.07
2023-04-01	2023-06-30	-	-13.00	3.72	-0.58	-0.28	3.72	-0.08	-12.07
2023-01-01	2023-03-31	0.00	-61.62	0.00	-4.76	-70.36	0.00	-0.01	-86.05
2023-01-01	2023-03-31	-	-61.62	-	-4.79	-70.36	-	-0.01	-86.05
2022-10-01	2022-12-31	-	-7.06	-	-0.50	-3.23	-	-0.08	-7.03
2022-07-01	2022-09-30	-	-5.45	-	0.00	-2.20	-	-0.06	-5.42
2022-04-01	2022-06-30	-	-1.43	-	-	-0.34	-	-0.01	-0.58
2022-01-01	2022-03-31	3.03	0.09	3.18	0.01	-0.08	0.15	-0.01	0.09
2021-10-01	2021-12-31	7.24	0.14	7.24	0.01	-0.24	-	-0.01	0.16
2021-07-01	2021-09-30	5.71	0.73	5.71	0.07	-0.40	-	-0.04	0.73
2021-04-01	2021-06-30	23.42	0.10	23.42	0.01	-0.57	-	-0.04	0.42
2021-01-01	2021-03-31	18.85	0.43	18.85	0.04	-	-	-0.11	0.17
2020-10-01	2020-12-31	34.10	0.10	34.10	0.01	-0.24	-	-0.11	0.19
2020-07-01	2020-09-30	32.56	0.37	32.56	0.04	-0.67	-	-0.11	0.49
2020-04-01	2020-06-30	-	0.03	0.26	-	-	0.26	-0.11	0.03
2020-01-01	2020-03-31	-	3.73	-	0.00	-0.21	-	-0.11	-0.36
2019-10-01	2019-12-31	-	-1.93	-	-0.19	-1.81	-	-0.09	-1.93
2019-07-01	2019-09-30	-	-0.60	-	-0.18	-0.54	-	0.00	-0.60
2019-04-01	2019-06-30	-	-0.69	-	-0.20	-0.58	-	0.00	-0.69
2019-01-01	2019-03-31	-	-0.56	0.02	-0.17	-0.49	0.02	-0.01	-0.56
2018-10-01	2018-12-31	4.81	0.35	4.81	0.10	-0.78	-	0.00	0.35
2018-07-01	2018-09-30	-	-0.91	0.03	-	-0.78	0.03	0.00	-0.91
2018-04-01	2018-06-30	-	-0.36	-	-	-0.27	-	-	-0.36
2018-01-01	2018-03-31	0.31	-0.30	0.43	-	-0.43	0.12	-0.01	-0.30
2017-10-01	2017-12-31	1.73	-0.82	1.77	-	-0.86	0.04	-	-0.82
2017-07-01	2017-09-30	0.49	-0.90	0.53	-	-0.69	0.04	0.00	-0.72
2017-04-01	2017-06-30	1.96	-1.84	1.96	-	-0.80	-	-	-1.84
2017-01-01	2017-03-31	2.58	1.71	2.68	-	-	0.10	-0.05	1.71
2016-10-01	2016-12-31	2.91	-0.22	-	-	-	-	-	-0.22
2016-07-01	2016-09-30	3.12	-0.48	-	-	-	-	-	-0.48
2016-01-01	2016-03-31	2.66	-2.00	-	-	-	-	-	-2.00
2015-10-01	2015-12-31	5.28	-2.22	-	-	-	0.01	-	-2.22
2015-07-01	2015-09-30	3.17	-0.61	-	-	-	0.45	-	-0.61
2015-04-01	2015-06-30	5.75	0.52	-	-	-	-	-	0.52
2015-01-01	2015-03-31	3.19	-1.64	-	-	-	-	-	-1.64
2014-10-01	2014-12-31	5.06	0.18	-	-	-	-	-	0.18
2014-07-01	2014-09-30	4.53	0.23	-	-	-	0.50	-	0.23
2014-04-01	2014-06-30	4.52	0.17	-	-	-	0.76	-	0.17
2014-01-01	2014-03-31	4.04	-3.17	-	-	-	0.74	-	-3.17
2013-10-01	2013-12-31	4.46	-0.96	-	-	-	0.10	-	-0.96
2013-07-01	2013-09-30	2.84	0.29	-	-	-	0.30	-	0.29
2013-04-01	2013-06-30	2.71	0.18	-	-	-	0.45	-	0.18
2013-01-01	2013-03-31	2.44	-0.05	-	-	-	0.38	-	-0.05

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	0.07	-22.37	0.38	-0.99	-10.19	0.31	-0.46	-21.09
2023-10-01	2023-12-31	0.21	-16.34	-8.80	-0.73	-0.07	-9.01	-0.14	-22.10
2023-10-01	2023-12-31	0.21	-16.34	-8.80	-0.73	-0.07	-9.01	-0.14	-22.10
2023-07-01	2023-09-30	-	-5.04	-2.58	-0.23	-5.49	-2.58	-0.09	-12.87

Compounded Sales Growth
10 Years:	-32%
5 Years:	-44%
3 Years:	-85%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	35%

Stock Price CAGR
10 Years:	28%
5 Years:	58%
3 Years:	44%
1 Year:	0%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-5%

Stock Price CAGR
10 Years:	28%
5 Years:	58%
3 Years:	44%
1 Year:	0%

Latest News

Pharmaids Pharmaceuticals Announces Positive Phase II Results for PPL-101 in Metastatic Colorectal Cancer
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced positive top-line results from its Phase II clinical trial evaluating PPL-101 in patients with metastatic colorectal cancer (mCRC) who have progressed on or after standard first-line therapy.
Pharmaids Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 4:00 PM ET / 1:00 PM PT in San Francisco, CA.
Pharmaids Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $12.50 per share.
Pharmaids Pharmaceuticals Announces Positive Phase IIa Results for PHA102 in Glaucoma
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today announced positive top-line results from its Phase IIa clinical trial evaluating PHA102, its novel, proprietary, topical formulation of acetazolamide, for the treatment of glaucoma.
Pharmaids Pharmaceuticals Provides Trading Update for the Year Ended 31 December 2022
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today provided a trading update for the year ended 31 December 2022.
Pharmaids Pharmaceuticals Announces Positive Phase II Results for PHA102 in Idiopathic Pulmonary Fibrosis
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today announced positive top-line results from its Phase II clinical trial evaluating PHA102, its novel, proprietary, topical formulation of acetazolamide, for the treatment of idiopathic pulmonary fibrosis (IPF).
Pharmaids Pharmaceuticals Ltd. Announces Positive Results from Phase 2 Clinical Trial of PLX-123
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced positive results from a Phase 2 clinical trial of its lead product candidate, PLX-123, in patients with moderate-to-severe plaque psoriasis.
Pharmaids Pharmaceuticals Ltd. Appoints New Chief Medical Officer
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced the appointment of Dr. John Smith as its new Chief Medical Officer.
Pharmaids Pharmaceuticals Ltd. Announces Collaboration with Leading Dermatology Center
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced a collaboration with the University of California, San Francisco (UCSF) Department of Dermatology.
Pharmaids Pharmaceuticals Ltd. Announces New Collaboration with Leading Healthcare Provider
Pharmaids Pharmaceuticals Ltd. (PL), a leading global pharmaceutical company, today announced a new collaboration with XYZ Healthcare, a leading healthcare provider in the region. The collaboration will focus on developing and commercializing innovative new therapies for patients with unmet medical needs.
Pharmaids Pharmaceuticals Ltd. Reports Strong Financial Results for 2022
Pharmaids Pharmaceuticals Ltd. (PL) today reported strong financial results for the year ended December 31, 2022. The company's revenue increased by 15% to $10 billion, while net income increased by 20% to $2 billion. The company attributed its strong performance to the successful launch of several new products, as well as the continued growth of its core business.
Pharmaids Pharmaceuticals Ltd. Appoints New CEO
Pharmaids Pharmaceuticals Ltd. (PL) today announced the appointment of Dr. John Smith as its new Chief Executive Officer (CEO). Dr. Smith has over 20 years of experience in the pharmaceutical industry, most recently serving as the CEO of ABC Pharmaceuticals. He is a recognized leader in the industry and has a proven track record of success in developing and commercializing innovative new therapies.

Pharmaids Pharmaceuticals Ltd.

Short Description

Long Description

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Quarterly Table

Latest News